Lv51
1520 积分 2024-08-30 加入
VP2-2024: Fuzuloparib with or without apatinib in HER2- metastatic breast cancer (mBC) patients (pts) with germline BRCA1/2 mutations (gBRCA1/2m): A randomized phase III trial
1个月前
已完结
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study
2个月前
已完结
Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer
4个月前
已完结
G-CSF, the guardian of granulopoiesis
7个月前
已完结
皖公网安备34019202002308
